XML 49 R19.htm IDEA: XBRL DOCUMENT

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2015
Subsequent event
Subsequent event	12. Subsequent event In October 2015, we earned a $15.0 million milestone from Novartis in connection with the approval of JAKAVI (ruxolitinib) in Japan for the treatment of patients with polycythemia vera. We will record this amount as contract revenue in the three months ended December 31, 2015.